Medicus Pharma CFO granted 250,000 stock options

Medicus Pharma Ltd. President and CFO Carolyn F. Bonner received a compensation-related stock option grant covering 250,000 common shares.

Rhea-AI Filing Summary

Medicus Pharma Ltd. President and CFO Carolyn F. Bonner received a compensation-related stock option grant covering 250,000 common shares. The option has an exercise price of $0.36 per share and expires on June 3, 2031.

According to the footnote, the award was granted on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. Following this grant, Bonner holds stock options for 250,000 underlying common shares directly. This is an equity incentive grant rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 250,000 shares

Grant/Award 1 txn

Insider Bonner Carolyn F.

Role President and CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	250,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 250,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Option grant size: 250,000 shares Exercise price: $0.36/share Options after transaction: 250,000 shares +3 more

6 metrics

Option grant size 250,000 shares Underlying common shares in new stock option award

Exercise price $0.36/share Stock option exercise price for the grant

Options after transaction 250,000 shares Total options held following the grant

Expiration date June 3, 2031 Stock option expiration date

Vesting schedule 4 quarterly installments over 1 year Footnote description of vesting

Grant date June 3, 2026 Footnote states option was granted on this date

Key Terms

Stock Option (right to buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2031-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"The option is scheduled to vest quarterly in four equal installments over one year."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medicus Pharma (MDCX) disclose about Carolyn Bonner’s new award?

Medicus Pharma reported that President and CFO Carolyn F. Bonner received a stock option grant for 250,000 common shares. The options are a compensation award, not an open-market purchase, and give her the right to buy shares at a fixed exercise price.

How many Medicus Pharma shares are covered by Carolyn Bonner’s new options?

The option grant covers 250,000 underlying common shares of Medicus Pharma. This entire amount is reflected as options held after the transaction, giving Bonner potential future ownership if she chooses to exercise the options once they vest.

What is the exercise price of Carolyn Bonner’s Medicus Pharma stock options?

The options have an exercise price of $0.36 per share. This means Bonner can buy up to 250,000 Medicus Pharma common shares at $0.36 each once the options vest and before they expire, regardless of the market price at that time.

When do Carolyn Bonner’s Medicus Pharma options vest and expire?

The options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. The grant has an expiration date of June 3, 2031, after which any unexercised options will no longer be usable.

Is Carolyn Bonner’s Form 4 transaction in MDCX a market buy or compensation grant?

The Form 4 shows a compensation-related grant, coded “A” for award or other acquisition, not a market purchase. Bonner received stock options for 250,000 shares at a $0.36 exercise price, reflecting an incentive grant from Medicus Pharma rather than an open-market trade.

How many Medicus Pharma options does Carolyn Bonner hold after this transaction?

After this grant, Bonner holds options covering 250,000 common shares directly. The Form 4’s “following transaction” figure matches the newly granted amount, indicating this award establishes her current reported option position in Medicus Pharma common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonner Carolyn F.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W.CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		250,000		(1)	06/03/2031	Common Shares	250,000	$0	250,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Carolyn F. Bonner	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)